ConductScience.org, home

Paper35548360

Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis.

Han M and 9 others. Front Pharmacol, 2022. Cited by 22 papers, by iCite.

Cite this record

ConductScience Library. Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis. Papers, record 35548360. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35548360

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis.
PubMed
Journal
Front Pharmacol
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
22
iCite
Relative citation ratio, by iCite
2.18
iCite
Revised in PubMed
2022-07-16
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Han MMeishan
2Song YYingjian
3Liu SSha
4Lu XXiaoyan
5Su LLinyu
6Liu MMeixuan
7Zhu XXiaosu
8Sun KKaoxiang
9Lu YYanan
10Wang AAiping

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133076918Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review.J Nanobiotechnology2020https://conductscience.org/library/papers/33076918PubMed
230742982Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer.Int J Pharm2019https://conductscience.org/library/papers/30742982PubMed
317244708Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/17244708PubMed
423372951A review of current and novel therapies for idiopathic pulmonary fibrosis.J Thorac Dis2013https://conductscience.org/library/papers/23372951PubMed
524535066Bronchoalveolar pH and inflammatory biomarkers in newly diagnosed IPF and GERD patients: a case-control study.Med Sci Monit2014https://conductscience.org/library/papers/24535066PubMed
628696894Preference of Aerosolized Pirfenidone to Oral Intake: An Experimental Model of Pulmonary Fibrosis by Paraquat.J Aerosol Med Pulm Drug Deliv2018https://conductscience.org/library/papers/28696894PubMed
721471066An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.Am J Respir Crit Care Med2011https://conductscience.org/library/papers/21471066PubMed
815947432Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung.J Med Microbiol2005https://conductscience.org/library/papers/15947432PubMed
926902722Enhanced pulmonary delivery of fluticasone propionate in rodents by mucus-penetrating nanoparticles.Int J Pharm2016https://conductscience.org/library/papers/26902722PubMed
1032575019Pirfenidone: A novel hypothetical treatment for COVID-19.Med Hypotheses2020https://conductscience.org/library/papers/32575019PubMed
1131935633Low-level laser therapy attenuates lung inflammation and airway remodeling in a murine model of idiopathic pulmonary fibrosis: Relevance to cytokines secretion from lung structural cells.J Photochem Photobiol B2020https://conductscience.org/library/papers/31935633PubMed
1221632796Antifibrotic activities of pirfenidone in animal models.Eur Respir Rev2011https://conductscience.org/library/papers/21632796PubMed
1328091615Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis.Sci Rep2017https://conductscience.org/library/papers/28091615PubMed
1429327616Nintedanib for the treatment of idiopathic pulmonary fibrosis.Expert Opin Pharmacother2018https://conductscience.org/library/papers/29327616PubMed
1529313004Nanoparticles in the clinic.Bioeng Transl Med2016https://conductscience.org/library/papers/29313004PubMed
1627005406Pirfenidone-induced severe phototoxic reaction in a patient with idiopathic lung fibrosis.J Eur Acad Dermatol Venereol2016https://conductscience.org/library/papers/27005406PubMed
1711673205Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.Am J Respir Crit Care Med2001https://conductscience.org/library/papers/11673205PubMed
1832703779Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.Eur Respir J2021https://conductscience.org/library/papers/32703779PubMed
1916146340Carrier-based strategies for targeting protein and peptide drugs to the lungs.AAPS J2005https://conductscience.org/library/papers/16146340PubMed
2026779535Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.Biomed Res Int2015https://conductscience.org/library/papers/26779535PubMed

See all 32 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.

PMIDTitleJournalYearIn PapersSource
42688889Molecular insights of a Unani formulation in targeting fibrosis-associated diseases.Front Pharmacol2026https://conductscience.org/library/papers/42688889PubMed
41361355Network pharmacology and in vitro studies demonstrate modulation of fibrotic pathways by Swertia chirayita in pulmonary fibrosis.Sci Rep2025https://conductscience.org/library/papers/41361355PubMed
41010139Recent Advances in pH-Responsive Liposomes: Lessons Learnt and New Directions in Nanomedicine Development.Materials (Basel)2025https://conductscience.org/library/papers/41010139PubMed
40241794SIRT3/6/7: promising therapeutic targets for pulmonary fibrosis.Front Cell Dev Biol2025https://conductscience.org/library/papers/40241794PubMed
39918485Citrus pectin-coated inhalable PLGA nanoparticles for treatment of pulmonary fibrosis.J Mater Chem B2025https://conductscience.org/library/papers/39918485PubMed
38065244Emerging delivery approaches for targeted pulmonary fibrosis treatment.Adv Drug Deliv Rev2024https://conductscience.org/library/papers/38065244PubMed
37608885Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies.Front Pharmacol2023https://conductscience.org/library/papers/37608885PubMed
36998607Arctiin-encapsulated DSPE-PEG bubble-like nanoparticles inhibit alveolar epithelial type 2 cell senescence to alleviate pulmonary fibrosis via the p38/p53/p21 pathway.Front Pharmacol2023https://conductscience.org/library/papers/36998607PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35548360

GET https://conductscience.org/api/papers/v1/35548360/references?page=2